ClinicalChemistry53:4666–672(2007)
CancerDiagnostics
MESOMARK:APotentialTestforMalignant
PleuralMesothelioma
HeatherL.Beyer,RyanD.Geschwindt,CurtisL.Glover,LyTran,
IngegerdHellstrom,Karl-ErikHellstrom,M.CraigMiller,ThorstenVerch,
W.JeffreyAllard,*HarveyI.Pass,andNiranjanY.Sardesai
TM
Background:Solublemesothelin-relatedpeptides(SMRP)havebeenreportedtobepotentialbiomarkersforma-lignantpleuralmesothelioma(MPM).Wereportanalyt-icalandpreliminaryclinicalstudiesofMESOMARKTM,aquantitativeassayforSMRP.
Methods:TheMESOMARKassayisa2-stepimmu-noenzymaticassayinanELISAformatwitha6-pointcalibrationcurve(0–32nmol/L).Weassessedanalyticalimprecision,analytestability,andanalyticalinterfer-ences.WemeasuredSMRPbythisassayin409appar-entlyhealthyindividuals(referenceintervalstudy),177patientswithnonmalignantconditions,and500cancerpatients,including88withMPM.
Results:Thelimitofdetectionwas0.16nmol/L.At2–19nmol/L,intraassayimprecision(CV)was1.1%–5.3%,andtotalimprecisionwas4.0%–11.0%.Themeandilu-tionrecoveryfor5sampleswas109%(range,99%–113%).Nointerferencewasseenfromaddedbilirubin(200mg/L),hemoglobin(500mg/L),triglycerides(30g/L),chemotherapeuticagents,orothertestedsub-stances.Recombinantmesothelinwasstableinserumuponfreeze/thawat 70°Canduponstorageforatleast7daysat2–8°C.The99thpercentileofthereferencegroupwas1.5nmol/L[95%confidenceinterval(CI),1.2–1.6nmol/L;n 409],andmeanSMRPwassignifi-cantlyhigherinserafrompatientswithMPM(7.5nmol/L;95%CI,2.8–12.1nmol/L;n 88).SMRPwasincreasedin52%and5%ofMPMpatientsandasbestos-exposedindividuals,respectively.Concentrationsinothernonmalignantandmalignantconditionsweresimilartothoseinhealthycontrols.
Conclusions:TheMESOMARKassayisanalyticallyrobustandmaybeusefulforthedetectionandmanage-mentofmesothelioma.
©2007AmericanAssociationforClinicalChemistry
Malignantmesotheliomaisahighlyaggressiveneoplasmwithpoorprognosis.Mesotheliomaaccountedfor 1.5%ofthe171900totallungandbronchusmalignanciesintheUSin2003(1,2),andepidemiologicalstudieshaveestab-lishedexposuretoasbestosfibersastheprimarycause(3–5).Althoughmalignantmesotheliomaremainsarela-tivelyuncommonmalignancyintheUS,itcontinuestobeanimportantcauseofmortalityinnumerousareasworld-wide,e.g.,England,Wales,continentalEurope,andAustralia.
Becausethediseaseisasymptomaticinearlystagesanddefinitivediagnosisisdifficult,detectiontypicallyoccursatalatestage,andrecurrencerates,eveninpatientswithsurgicallyresectedtumors,areveryhigh.Treatmentefficacyisroutinelyassessedbyclinicalsymp-tomsandcostlyradiologicimagingtechniqueswithlim-itedsensitivityandspecificity(6).Thus,therehasbeenanincreasingneedforasimplediagnosticbloodtestforscreeningasbestos-exposedpatientsaswellasformoni-toringresponsetotreatment.
TheMESOMARK assaymeasuressolublemoleculesthatarerelatedtothemesothelin/megakaryocytepoten-tiatingfactor(MPF)1familyofproteinsandrecognizedbythemonoclonalantibodyOV569(7).MesothelinandMPFaresynthesizedtogetherasa69-kDaprecursorfromwhichanN-terminal31-kDafragmentisreleasedasMPF,andmesothelinisthe40-kDaC-terminalmembrane-boundfragment.Immunohistochemicalstudiesrevealed
ResearchandDevelopmentDivision,FujirebioDiagnostics,Inc.,Malvern,PA.
*Addresscorrespondencetothisauthorat:ResearchandDevelopmentDivision,FujirebioDiagnostics,Inc.,201GreatValleyPkwy.,Malvern,PA19355.Fax610-240-3803;e-mailallardj@fdi.com.
ReceivedAugust31,2006;acceptedDecember22,2006.
PreviouslypublishedonlineatDOI:10.1373/clinchem.2006.079327
Nonstandardabbreviations:MPF,megakaryocytepotentiatingfactor;SMRP,solublemesothelin-relatedpeptides;HAMA,humanantimouseanti-body;RF,rheumatoidfactor;AUC,areaunderthecurve;CI,confidenceinterval.
1
666
A Clinical observation of the therapy for malignant hydrothorax by intra-thoracic injection…… 隐藏>> A ic svai hetClnialobertonoft heryf alap ormignan t hd...
Controlled-Release Oxycodone Alone or Combined with Gabapentin for Management of Malignant Neuro_专业资料。CiJacre13:08,09hn ne s()—620 CR28 wwsrgrn,o ...
Controlled-Release Oxycodone Alone or Combined with Gabapentin for Management of Malignant Neuro_专业资料。CiJacre13:08,09hn ne s()—620 CR28 wwsrgrn,o ...
热门文档